US · Healthcare · Biotechnology
EPS came in at -0.77 against a street estimate of -0.89 — a beat of 13.5%.
Analysts rate Kura Oncology Inc a strong buy (13 buy, 2 hold, 0 sell out of 15) with an average price target of $32.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.83% |
| Suvretta Capital Management, LLC | 9.64% |
| Bvf Inc | 9.49% |
| State Street Corp | 5.07% |
| Vanguard Capital Management, LLC | 4.26% |
| Armistice Capital, LLC | 4.20% |
| AQR Capital Management LLC | 2.39% |
| Geode Capital Management, LLC | 2.29% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 KURA ONCOLOGY, INC. - 8-K SUMMARY HEADLINE NUMBERS • Kura Oncology formed wholly-owned subsidiary Caspian Therapeutics, Inc. on September 8, 2026 • | 2026-09-09 |
| Board / officer change · Q3 2026 KURA ONCOLOGY, INC. - 8-K SUMMARY HEADLINE NUMBERS • Jennifer Fulk appointed as Chief Financial Officer effective September 8, 2026 • Annual base sa | 2026-09-08 |
| Quarterly report · Q2 2026 KURA ONCOLOGY, INC. – 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash Position: $70.2 million in cash and cash equivalents | 2026-08-12 |
| Results announced · Q3 2026 KURA ONCOLOGY Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Net product revenue (KOMZIFTI): $9.1 million in Q2 2026, up 57% from Q1 2026 • Ne | 2026-08-12 |
| Board / officer change · Q3 2026 KURA ONCOLOGY, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company: Kura Oncology, Inc. (Nasdaq: KURA), oncology-focused biopharmaceutical company based i | 2026-07-29 |
| Board / officer change · Q2 2026 KURA ONCOLOGY, INC. — 8-K SUMMARY HEADLINE NUMBERS • 88,762,704 shares of common stock outstanding as of April 6, 2026 (record date) • 69,778,580 sh | 2026-06-04 |
| Quarterly report · Q1 2026 KURA ONCOLOGY, INC. – 10-Q SUMMARY (Q1 2026) HEADLINE NUMBERS • Cash Position Declined Sharply: Cash and cash equivalents fell from $149.1 million ( | 2026-05-12 |
| Proxy statement · Q2 2026 KURA ONCOLOGY, INC. — 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect three Class III director nominees for th | 2026-04-10 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kura Oncology Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.